Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000

LIPELLA PHARMACEUTICALS INC.

Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.
Amendment modifies existing Certificate of Designation, potentially altering voting or conversion rights of current holders.
Change in authorized shares may indicate future financing or strategic moves by the company.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LIPELLA PHARMACEUTICALS INC.: Increased the number of designated Series C Voting Convertible Preferred Stock shares from 1,050,000 to 1,260,000 (effective 2025-04-08).

Change: charter amendment
Effective: 2025-04-08

Exact text from the filing

On April 8, 2025, the Company filed a Certificate of Amendment of Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock (the “Series C Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Series C Certificate of Amendment amended the Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock of the Company (the “Certificate of Designation”) to increase the number of shares of the Company’s Series C Voting Convertible Preferred Stock, par value $0.0001 per share, designated pursuant to the Certificate of Designation from 1,050,000 shares to 1,260,000 shares.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-25-000604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.